NCT03532087 - Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer | Biotech Hunter

Timeline

Start Date

February 28, 2018

Primary Completion Date

February 28, 2021

Study Completion Date

June 30, 2023

Conditions

Breast Neoplasms

Interventions

DRUG

Denosumab 120 mg

Denosumab 120 mg every 3 weeks.

DRUG

Denosumab 60 mg

Denosumab 60 mg every 6 months.

Trial Locations (8)

Ziekenhuisgroep Twente (Twenteborg ZH Almelo), Almelo

Gelre ziekenhuizen, Apeldoorn

Zuyderland Medisch Centrum (Heerlen), Heerlen

Spaarne Gasthuis (Hoofddorp), Hoofddorp

Leiden University Medical Center, Leiden

Fransiscus (Vlietland), Schiedam

VieCuri Medisch Centrum (Venlo), Venlo

't Lange Land Ziekenhuis, Zoetermeer